Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of parkinson's disease

Molecular Neurobiology

Volumn 41, Issue 2-3, 2010, Pages 410-419

  McCollum, Mark ^a   Ma, Zhiyuan ^a   Cohen, Eric ^a   Leon, Rebecca ^a   Tao, Rui ^a   Wu, Jang Yen ^a   Maharaj, Dipnarine ^b   Wei, Jianning ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b South Florida Bone Marrow Stem Cell Transplant Institute   (United States)

Author keywords

G CSF. Dopaminergic neurons; MPTP; Neurogenesis; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BROXURIDINE; DOPAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; POTASSIUM ION; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN FUNCTION; CELL LABELING; CELL PROLIFERATION; CELL REGENERATION; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MICRODIALYSIS; MOTOR ACTIVITY; MPTP POISONING; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; MOTOR ACTIVITY; MPTP POISONING; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 77955089797     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12035-010-8118-4     Document Type: Conference Paper

References (31)

1. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson's disease therapy. Ann Neurol 53:S3-S15
2. Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78:2791-2808
3. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schabitz WR (2005) The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115:2083-2098
4. Schneider A, Kuhn HG, Schabitz WR (2005) A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4:1753-1757
5. Komine-Kobayashi M, Zhang N, Liu M, Tanaka R, Hara H, Osaka A, Mochizuki H, Mizuno Y, Urabe T (2006) Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab 26:402-413
6. Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, Sommer C, Schwab S (2003) Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 34:745-751
7. Cao XQ, Arai H, Ren YR, Oizumi H, Zhang N, Seike S, Furuya T, Yasuda T, Mizuno Y, Mochizuki H (2006) Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels. J Neurochem 99:861-867
8. Meuer K, Pitzer C, Teismann P, Kruger C, Goricke B, Laage R, Lingor P, Peters K, Schlachetzki JC, Kobayashi K, Dietz GP, Weber D, Ferger B, Schabitz WR, Bach A, Schulz JB, Bahr M, Schneider A, Weishaupt JH (2006) Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem 97:675-686
9. Lee ST, Park JE, Kim DH, Kim S, Im WS, Kang L, Jung SH, Kim MW, Chu K, Kim M (2008) Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease. Brain Res 1194:130-137
10. Gibson CL, Philip MW, Murphy SP (2005) G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 25:431-439
11. Lu CZ, Xiao BG (2007) Neuroprotection of G-CSF in cerebral ischemia. Front Biosci 12:2869-2875
12. Ming GL, Song H (2005) Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 28:223-250
13. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7:726-735
14. Liu B, Gao E, Zeng X, Ji M, Cai Q, Lu Q, Yang H, Xu Q (2006) Proliferation of neural precursors in the subventricular zone after chemical lesions of the nigrostriatal pathway in rat brain. Brain Res 1106:30-39
15. Yoshimi K, Ren YR, Seki T, Yamada M, Ooizumi H, Onodera M, Saito Y, Murayama S, Okano H, Mizuno Y (2005) Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann Neurol 58:31-40
16. Jordan JD, Ming GL, Song H (2006) Adult neurogenesis as a potential therapy for neurodegenerative diseases. Discov Med 6:144-147
17. Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132:645-660
18. Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2:141-151
19. Huang HY, Lin SZ, Kuo JS, Chen WF, Wang MJ (2007) G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via the ERK pathway. Neurobiol Aging 28:1258-1269
20. Shan X, Chi L, Bishop M, Luo C, Lien L, Zhang Z, Liu R (2006) Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of MPTP-induced Parkinson's disease-like mice. Stem Cells 24:1280-1287
21. Zhao M, Momma S, Delfani K, Carlen M, Cassidy RM, Johansson CB, Brismar H, Shupliakov O, Frisen J, Janson AM (2003) Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 100:7925-7930
22. Frielingsdorf H, Schwarz K, Brundin P, Mohapel P (2004) No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 101:10177-10182
23. Mao L, Lau YS, Petroske E, Wang JQ (2001) Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration. Brain Res Dev Brain Res 131:57-65
24. Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH (2002) The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 22:6639-6649
25. Kay JN, Blum M (2000) Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Dev Neurosci 22:56-67
26. Horner PJ, Gage FH (2000) Regenerating the damaged central nervous system. Nature 407:963-970
27. Fallon J, Reid S, Kinyamu R, Opole I, Opole R, Baratta J, Korc M, Endo TL, Duong A, Nguyen G, Karkehabadhi M, Twardzik D, Patel S, Loughlin S (2000) In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci USA 97:14686-14691
28. Benraiss A, Chmielnicki E, Lerner K, Roh D, Goldman SA (2001) Adenoviral brain-derived neurotrophic factor induces both neo-striatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci 21:6718-6731
29. Sedelis M, Schwarting RKW, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125
30. Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Launay JM, Cohen-Salmon C, Hirsch EC (2003) Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 14:218-228
31. Espejo EF, Minano J (2001) Adrenergic hyperactivity and metanephrine excess in the nucleus accumbens after prefronto-cortical dopamine depletion. J Neurophysiol 85:1270-1274